High-flow nasal cannula failure in critically ill cancer patients with acute respiratory failure: Moving from avoiding intubation to avoiding delayed intubation.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
12
2021
accepted:
04
06
2022
entrez:
29
6
2022
pubmed:
30
6
2022
medline:
2
7
2022
Statut:
epublish
Résumé
High-flow nasal cannula (HFNC) is increasingly used in critically ill cancer patients with acute respiratory failure (ARF) to avoid mechanical ventilation (MV). The objective was to assess prognostic factors associated with mortality in ICU cancer patients requiring MV after HFNC failure, and to identify predictive factors of intubation. We conducted a retrospective study from 2012-2016 in a cancer referral center. All consecutive onco-hematology adult patients admitted to the ICU treated with HFNC were included. HFNC failure was defined by intubation requirement. 202 patients were included, 104 successfully treated with HFNC and 98 requiring intubation. ICU and hospital mortality rates were 26.2% (n = 53) and 42.1% (n = 85) respectively, and 53.1% (n = 52) and 68.4% (n = 67) in patients requiring MV. Multivariate analysis identified 4 prognostic factors of hospital mortality after HFNC failure: complete/partial remission (OR = 0.2, 95%CI = 0.04-0.98, p<0.001) compared to patients with refractory/relapse disease (OR = 3.73, 95%CI = 1.08-12.86), intubation after day 3 (OR = 7.78, 95%CI = 1.44-41.96), number of pulmonary quadrants involved on chest X-ray (OR = 1.93, 95%CI = 1.14-3.26, p = 0.01) and SAPSII at ICU admission (OR = 1.06, 95%CI = 1-1.12, p = 0.019). Predictive factors of intubation were the absence of sepsis (sHR = 0.32, 95%CI = 0.12-0.74, p = 0.0087), Sp02<95% 15 minutes after HFNC initiation (sHR = 2.05, 95%CI = 1.32-3.18, p = 0.0014), number of quadrants on X-ray (sHR = 1.73, 95%CI = 1.46-2.06, p<0.001), Fi02>60% at HFNC initiation (sHR = 3.12, 95%CI = 2.06-4.74, p<0.001) and SAPSII at ICU admission (sHR = 1.03, 95%CI = 1.02-1.05, p<0.01). Duration of HFNC may be predictive of an excess mortality in ARF cancer patients. Early warning scores to predict HFNC failure are needed to identify patients who would benefit from early intubation.
Sections du résumé
BACKGROUND
High-flow nasal cannula (HFNC) is increasingly used in critically ill cancer patients with acute respiratory failure (ARF) to avoid mechanical ventilation (MV). The objective was to assess prognostic factors associated with mortality in ICU cancer patients requiring MV after HFNC failure, and to identify predictive factors of intubation.
METHODS
We conducted a retrospective study from 2012-2016 in a cancer referral center. All consecutive onco-hematology adult patients admitted to the ICU treated with HFNC were included. HFNC failure was defined by intubation requirement.
RESULTS
202 patients were included, 104 successfully treated with HFNC and 98 requiring intubation. ICU and hospital mortality rates were 26.2% (n = 53) and 42.1% (n = 85) respectively, and 53.1% (n = 52) and 68.4% (n = 67) in patients requiring MV. Multivariate analysis identified 4 prognostic factors of hospital mortality after HFNC failure: complete/partial remission (OR = 0.2, 95%CI = 0.04-0.98, p<0.001) compared to patients with refractory/relapse disease (OR = 3.73, 95%CI = 1.08-12.86), intubation after day 3 (OR = 7.78, 95%CI = 1.44-41.96), number of pulmonary quadrants involved on chest X-ray (OR = 1.93, 95%CI = 1.14-3.26, p = 0.01) and SAPSII at ICU admission (OR = 1.06, 95%CI = 1-1.12, p = 0.019). Predictive factors of intubation were the absence of sepsis (sHR = 0.32, 95%CI = 0.12-0.74, p = 0.0087), Sp02<95% 15 minutes after HFNC initiation (sHR = 2.05, 95%CI = 1.32-3.18, p = 0.0014), number of quadrants on X-ray (sHR = 1.73, 95%CI = 1.46-2.06, p<0.001), Fi02>60% at HFNC initiation (sHR = 3.12, 95%CI = 2.06-4.74, p<0.001) and SAPSII at ICU admission (sHR = 1.03, 95%CI = 1.02-1.05, p<0.01).
CONCLUSION
Duration of HFNC may be predictive of an excess mortality in ARF cancer patients. Early warning scores to predict HFNC failure are needed to identify patients who would benefit from early intubation.
Identifiants
pubmed: 35767521
doi: 10.1371/journal.pone.0270138
pii: PONE-D-21-38946
pmc: PMC9242496
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0270138Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Respir Care. 2014 Oct;59(10):1517-23
pubmed: 25233383
J Clin Oncol. 2013 Aug 1;31(22):2810-8
pubmed: 23752112
Respir Med. 2009 Oct;103(10):1400-5
pubmed: 19467849
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Leuk Lymphoma. 2013 Aug;54(8):1724-9
pubmed: 23185988
Am J Respir Crit Care Med. 2017 Jan 1;195(1):67-77
pubmed: 27753501
Anaesthesia. 2016 Sep;71(9):1081-90
pubmed: 27418297
Intensive Care Med. 2006 Jan;32(1):3-5
pubmed: 16308682
Intensive Care Med. 2019 May;45(5):563-572
pubmed: 30888444
Ann Intensive Care. 2016 Dec;6(1):102
pubmed: 27783381
Intensive Care Med. 2006 Jun;32(6):808-22
pubmed: 16715324
Chest. 2017 Apr;151(4):764-775
pubmed: 28089816
Respir Care. 2019 Nov;64(11):1333-1342
pubmed: 31213571
Br J Anaesth. 2009 Dec;103(6):886-90
pubmed: 19846404
Blood Rev. 2015 Nov;29(6):359-67
pubmed: 25998991
Respir Care. 2010 Apr;55(4):408-13
pubmed: 20406507
Am J Respir Crit Care Med. 2010 Oct 15;182(8):1038-46
pubmed: 20581167
Intensive Care Med. 2015 Apr;41(4):623-32
pubmed: 25691263
J Crit Care. 2017 Dec;42:1-5
pubmed: 28641231
PLoS One. 2020 Jun 10;15(6):e0234495
pubmed: 32520960
Eur J Radiol. 2011 Dec;80(3):e536-43
pubmed: 21292416
Ann Intensive Care. 2021 Jan 27;11(1):17
pubmed: 33501590
Intensive Care Med. 2017 Feb;43(2):192-199
pubmed: 27812731
J Crit Care. 2012 Jun;27(3):324.e9-13
pubmed: 21958974
Respir Care. 2012 Nov;57(11):1873-8
pubmed: 22417844
Intensive Care Med. 2015 Nov;41(11):2008-10
pubmed: 26239727
J Crit Care. 2012 Oct;27(5):434-9
pubmed: 22762937
Expert Rev Respir Med. 2018 Oct;12(10):867-880
pubmed: 30101630
JAMA. 2018 Nov 27;320(20):2099-2107
pubmed: 30357270
Am J Respir Crit Care Med. 2021 Jul 15;204(2):187-196
pubmed: 33751920
J Crit Care. 2015 Dec;30(6):1174-8
pubmed: 26410680
Eur Respir J. 2018 Aug 9;52(2):
pubmed: 29976650
Lancet Respir Med. 2019 Feb;7(2):173-186
pubmed: 30529232
Intensive Care Med. 2017 Sep;43(9):1366-1382
pubmed: 28725926
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376
pubmed: 30576221
Intensive Care Med. 2016 Sep;42(9):1336-49
pubmed: 26969671
JAMA. 2015 Oct 27;314(16):1711-9
pubmed: 26444879
Am J Respir Crit Care Med. 2020 Aug 15;202(4):558-567
pubmed: 32325004
N Engl J Med. 2015 Jun 4;372(23):2185-96
pubmed: 25981908
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Crit Care. 2017 Apr;38:295-299
pubmed: 28038339
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
N Engl J Med. 2001 Feb 15;344(7):481-7
pubmed: 11172189
Thorax. 2008 Oct;63 Suppl 6:vi1-68
pubmed: 18838559
Minerva Anestesiol. 2012 Jul;78(7):836-41
pubmed: 22531566
Crit Care Med. 2016 Feb;44(2):282-90
pubmed: 26584191
Intensive Care Med. 2017 Dec;43(12):1808-1819
pubmed: 28948369
Minerva Anestesiol. 2014 Jun;80(6):712-25
pubmed: 24280820
Ann Intensive Care. 2016 Dec;6(1):45
pubmed: 27207177
J Crit Care. 2010 Sep;25(3):463-8
pubmed: 19781896